The healthcare bill to be voted on Sunday in the House contains the provision for a 12 year patent protection for new drugs. The is particularly important to biologic drug makers, Amgn, Genz, and Biib, because they sell very expensive mAb drugs. If the bill is passed there is a potential to cut cost by reducing expensive tests such as MRI, PET and CT scans, and even unnecessary little biopsies doctors order without restraint. See the following clip. Whether the new payment method will be effective in reducing spiraling healthcare cost remains to be seen.